Stress free therapy for COPD

Tetsuya Homma0 sites20 target enrollmentJanuary 13, 2022

Overview

No summary available.

Registry

who.int

Start Date

January 13, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

Tetsuya Homma

•Research subjects (those who meet all of the following items)
•Have been diagnosed with COPD and are outpatient
•(2\) COPD is a patient who falls under stage II or stage III in the GOLD classification.
•Patients with a CAT score of 10 points or higher and an mMRC of grade 1 or higher
•Patients whose general condition is stable
•Patients whose age at the time of obtaining consent is 40 to 80 years old

•Exclusion criteria
•Patients with a history of affecting the evaluation items (neurological disorders, osteoarthritis, etc.)
•Contraindications for physical therapy
•Users of implantable electronic devices (pacemakers, etc.), patients with heart disease, malignant tumor, tuberculous disease, or acute disease, those who are extremely debilitated, pregnant women or those who may become pregnant, perception / skin by atopy, etc. Persons with hypersensitivity, possible impaired blood flow, using metal implants, history of or suspected of having epilepsy.
•Others who are deemed inappropriate by the doctor.
•In the following cases, it is at the discretion of the doctor. Abnormal blood pressure, fever, or infectious disease, etc.
•Patients who cannot attach electrodes due to skin diseases, etc.
•Patients who changed or added the main drug therapy of COPD during the study period from the time of obtaining consent
•Those who the doctor in charge judges to be inappropriate for participation in the research
•Those who receive stress\-free therapy on a daily basis